CN106986869A - 用于抗病毒治疗的化合物和方法 - Google Patents

用于抗病毒治疗的化合物和方法 Download PDF

Info

Publication number
CN106986869A
CN106986869A CN201710094970.6A CN201710094970A CN106986869A CN 106986869 A CN106986869 A CN 106986869A CN 201710094970 A CN201710094970 A CN 201710094970A CN 106986869 A CN106986869 A CN 106986869A
Authority
CN
China
Prior art keywords
alkyl
compound
cycloalkyl
aryl
heterocyclic radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710094970.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·谢格尔
D·斯佩兰迪奥
杨海
M·桑吉
J·P·帕里什
许汉中
R·L·麦克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of CN106986869A publication Critical patent/CN106986869A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201710094970.6A 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法 Pending CN106986869A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625480P 2012-04-17 2012-04-17
US61/625,480 2012-04-17
CN201380030470.6A CN104583211A (zh) 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380030470.6A Division CN104583211A (zh) 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法

Publications (1)

Publication Number Publication Date
CN106986869A true CN106986869A (zh) 2017-07-28

Family

ID=48190648

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710094970.6A Pending CN106986869A (zh) 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法
CN201380030470.6A Pending CN104583211A (zh) 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380030470.6A Pending CN104583211A (zh) 2012-04-17 2013-04-17 用于抗病毒治疗的化合物和方法

Country Status (24)

Country Link
US (4) US8980878B2 (2)
EP (1) EP2838900B1 (2)
JP (3) JP2015516976A (2)
KR (2) KR102181318B1 (2)
CN (2) CN106986869A (2)
AU (1) AU2013249280B2 (2)
CA (1) CA2870024C (2)
CY (1) CY1122292T1 (2)
DK (1) DK2838900T3 (2)
EA (1) EA027855B1 (2)
ES (1) ES2750153T3 (2)
HK (1) HK1209745A1 (2)
HR (1) HRP20191754T1 (2)
HU (1) HUE045727T2 (2)
IL (1) IL235062A0 (2)
IN (1) IN2014DN09173A (2)
LT (1) LT2838900T (2)
MX (1) MX355781B (2)
NZ (1) NZ701647A (2)
PL (1) PL2838900T3 (2)
PT (1) PT2838900T (2)
SG (2) SG11201406736VA (2)
SI (1) SI2838900T1 (2)
WO (1) WO2013158776A1 (2)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34392B1 (fr) 2010-06-24 2013-07-03 Gilead Sciences Inc Pyrimidines en tant qu'agents antiviraux
CA2858096C (en) 2011-12-22 2020-06-23 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
CN106986869A (zh) * 2012-04-17 2017-07-28 吉利德科学公司 用于抗病毒治疗的化合物和方法
NZ716822A (en) 2013-08-21 2017-10-27 Alios Biopharma Inc Antiviral compounds
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
RU2017115670A (ru) * 2014-10-10 2018-11-15 Аблинкс Н.В. Лечение инфекции рсв
AU2015359624B2 (en) * 2014-12-08 2020-01-02 Janssen Sciences Ireland Uc Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)
US10131673B2 (en) * 2014-12-08 2018-11-20 Janssen Sciences Ireland Uc Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
JP2018076234A (ja) * 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
JO3637B1 (ar) * 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
SG11201808907PA (en) 2016-04-15 2018-11-29 Blueprint Medicines Corp Inhibitors of activin receptor-like kinase
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
JP7262118B2 (ja) 2016-10-06 2023-04-21 オーバス セラピューティクス インコーポレイテッド 医薬組成物およびその使用
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CA3077309A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as rsv inhibitors
US11427610B2 (en) * 2017-10-16 2022-08-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019079649A1 (en) 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
TW201932470A (zh) * 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
JP6804790B1 (ja) 2017-12-07 2020-12-23 エモリー ユニバーシティー Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
MA52348A (fr) * 2018-04-23 2021-03-03 Janssen Sciences Ireland Unlimited Co Composés hétéroaromatiques ayant une activité contre vrs
WO2020138015A1 (ja) 2018-12-27 2020-07-02 大正製薬株式会社 ピラゾロ［１，５－ａ］ピリミジン大環状化合物
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
CN116528850B (zh) * 2020-10-28 2025-08-22 盐野义制药株式会社 具有抗病毒活性的酰胺衍生物
CN113264929B (zh) * 2021-05-02 2023-10-10 润生药业有限公司 一种噻托溴铵的制备方法
JP7454729B2 (ja) * 2022-04-27 2024-03-22 塩野義製薬株式会社 抗ウイルス活性を有するアミド誘導体を含有する医薬組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
CN101460507A (zh) * 2006-04-06 2009-06-17 贝林格尔.英格海姆国际有限公司 噻唑基-二氢-吲唑
CN101460167A (zh) * 2006-04-06 2009-06-17 贝林格尔.英格海姆国际有限公司 用作pi3-激酶抑制剂的噻唑基-二氢-环戊二烯并吡唑
WO2010104306A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2011163518A1 (en) * 2010-06-24 2011-12-29 Gilead Sciences, Inc. Pyrazolo [1, 5 -a] pyrimidines as antiviral agents
CN102395579A (zh) * 2009-02-17 2012-03-28 百时美施贵宝公司 丙型肝炎病毒抑制剂

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (2) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US6342501B1 (en) 1994-02-25 2002-01-29 The Regents Of The University Of Michigan Pyrrolo[2,3-d] pyrimidines as antiviral agents
US5543413A (en) 1994-02-25 1996-08-06 Regents Of The University Of Michigan Heterocyclic thioamides and related analogs as antiviral agents with a unique mode of action
EP0767792A4 (en) 1994-06-29 2002-11-20 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
BR9908004A (pt) 1998-02-17 2001-12-18 Tularik Inc Composto, composição e método para prevençãoou supressão de uma infecção viral
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
TWI225488B (en) 1999-12-21 2004-12-21 Janssen Pharmaceutica Nv Derivatives of homopiperidinyl substituted benzimidazole analogues
CA2478715A1 (en) 2002-03-13 2003-09-25 Pharmacia & Upjohn Company Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators
JP2005529919A (ja) 2002-05-10 2005-10-06 スミスクライン ビーチャム コーポレーション 治療用化合物
US7196111B2 (en) 2002-06-04 2007-03-27 Schering Corporation Pyrazolo[1,5a]pyrimidine compounds as antiviral agents
DE10247271A1 (de) 2002-10-10 2004-08-26 Grünenthal GmbH Substituierte C-Imidazo[1,2-a]pyridin-3-yle
BRPI0418127A (pt) 2003-12-24 2007-04-27 Biota Scient Management uso de um composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, método para o tratamento de infecções envolvendo vìrus da sub-famìlia pneumovirinae, formulação farmacêutica, métodos para tratar mamìferos infectados e para prevenir a infecção de mamìferos com vìrus da sub-famìlia pneumovirinae, composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, composto e a forma n-óxido e sal piridìnio do mesmo, e, método de separação de enantiÈmeros de um composto
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
US20100055071A1 (en) 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
AU2008334948B2 (en) 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
CA2709883A1 (en) 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
US20110009429A1 (en) 2008-02-26 2011-01-13 Paul Oakley Heterocyclic compounds as inhibitors of cxcr2
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
US20110275673A1 (en) 2008-09-19 2011-11-10 Yibin Xiang Inhibitors of sphingosine kinase 1
EP2182081B1 (de) 2008-10-29 2014-01-22 Neue Materialien Bayreuth GmbH Verfahren zur thermischen Behandlung eines beschichteten Stahlblechkörpers
SI2373172T1 (sl) 2008-12-03 2013-12-31 Presidio Pharmaceuticals, Inc. Inhibitorji HCV NS5A
JP2012512877A (ja) 2008-12-18 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング セロトニン５−ｈｔ２ｂ受容体阻害剤
CA2740193A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
KR101411889B1 (ko) 2009-02-27 2014-06-27 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
JP5642661B2 (ja) 2009-03-05 2014-12-17 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
UA118080C2 (uk) 2009-06-11 2018-11-26 Еббві Айрленд Анлімітед Компані Противірусні сполуки
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
CN102471324B (zh) * 2009-08-07 2014-12-17 泰博特克药品公司 作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
CA2800509A1 (en) * 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
BR122020020745B8 (pt) * 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
CA2858096C (en) 2011-12-22 2020-06-23 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
CN106986869A (zh) 2012-04-17 2017-07-28 吉利德科学公司 用于抗病毒治疗的化合物和方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
CN101460507A (zh) * 2006-04-06 2009-06-17 贝林格尔.英格海姆国际有限公司 噻唑基-二氢-吲唑
CN101460167A (zh) * 2006-04-06 2009-06-17 贝林格尔.英格海姆国际有限公司 用作pi3-激酶抑制剂的噻唑基-二氢-环戊二烯并吡唑
CN102395579A (zh) * 2009-02-17 2012-03-28 百时美施贵宝公司 丙型肝炎病毒抑制剂
WO2010104306A2 (ko) * 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2011163518A1 (en) * 2010-06-24 2011-12-29 Gilead Sciences, Inc. Pyrazolo [1, 5 -a] pyrimidines as antiviral agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STN: "《STN-REGISTRY -L5》", 《STN-REGISTRY》 *

Also Published As

Publication number Publication date
KR102181318B1 (ko) 2020-11-20
DK2838900T3 (da) 2019-10-14
JP2015516976A (ja) 2015-06-18
JP2018095657A (ja) 2018-06-21
MX2014012450A (es) 2015-04-08
KR20140145615A (ko) 2014-12-23
US20150238501A1 (en) 2015-08-27
LT2838900T (lt) 2019-11-11
HRP20191754T1 (hr) 2020-01-24
WO2013158776A1 (en) 2013-10-24
HK1209745A1 (en) 2016-04-08
KR20200044971A (ko) 2020-04-29
EP2838900A1 (en) 2015-02-25
ES2750153T3 (es) 2020-03-25
US9504689B2 (en) 2016-11-29
US20170029427A1 (en) 2017-02-02
US10174038B2 (en) 2019-01-08
PL2838900T3 (pl) 2020-02-28
EA201491889A1 (ru) 2015-03-31
AU2013249280A1 (en) 2014-11-06
CN104583211A (zh) 2015-04-29
SG10201610166VA (en) 2017-01-27
CA2870024A1 (en) 2013-10-24
HK1207076A1 (en) 2016-01-22
CA2870024C (en) 2020-04-07
PT2838900T (pt) 2019-11-15
AU2013249280B2 (en) 2017-10-12
SG11201406736VA (en) 2015-03-30
US8980878B2 (en) 2015-03-17
EP2838900B1 (en) 2019-08-21
IL235062A0 (en) 2014-12-31
US20130273037A1 (en) 2013-10-17
JP2017128596A (ja) 2017-07-27
HUE045727T2 (hu) 2021-12-28
SI2838900T1 (sl) 2019-10-30
JP6291103B2 (ja) 2018-03-14
MX355781B (es) 2018-04-30
NZ701647A (en) 2016-05-27
US20170342079A1 (en) 2017-11-30
CY1122292T1 (el) 2021-01-27
IN2014DN09173A (2) 2015-07-10
KR102102283B1 (ko) 2020-04-21
EA027855B1 (ru) 2017-09-29

Similar Documents

Publication Publication Date Title
CN106986869A (zh) 用于抗病毒治疗的化合物和方法
TWI626050B (zh) 吡唑並［１，５-ａ］嘧啶類之醫藥組成物與用途
JP2023535701A (ja) 抗ウイルス剤としての官能化ペプチド
CN109641873B (zh) N-(吡啶-2-基)吡啶-磺酰胺衍生物及其用于疾病治疗的用途
CN105777754B (zh) 吡咯并嘧啶化合物
CN112105385A (zh) Irak降解剂和其用途
CN106795147B (zh) 作为β-分泌酶抑制剂的环丙基稠合噻嗪-2-胺化合物和使用方法
TW202140494A (zh) 作為抗病毒劑之雜環化合物、藥物組合物及其用途
US12286423B2 (en) Antiviral 1,3-di-oxo-indene compounds
CN105189497B (zh) 作为janus激酶抑制剂的n-(2-氰基杂环基)吡唑并吡啶酮
WO2021218997A1 (zh) 取代的氮杂五元环类化合物及其在药物中的应用
WO2021218992A1 (zh) 取代的吡咯烷类化合物及其在药物中的应用
US12565494B2 (en) Inhibitors of human respiratory syncytial virus and metapneumovirus
HK40088987A (zh) 作为rho-激酶抑制剂的二氢呋喃并吡啶衍生物
HK40118965A (zh) 作为janus激酶抑制剂的杂环衍生物
HK1223914B (en) Inhibitors of influenza viruses replication

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170728

WD01 Invention patent application deemed withdrawn after publication